RESUMO
In April 2019, the US Food and Drug Administration, in conjunction with 11 professional ophthalmic, vision science, and optometric societies, convened a forum on laser-based imaging. The forum brought together the Food and Drug Administration, clinicians, researchers, industry members, and other stakeholders to stimulate innovation and ensure that patients in the US are the first in the world to have access to high-quality, safe, and effective medical devices. This conference focused on the technology, clinical applications, regulatory issues, and reimbursement issues surrounding innovative ocular imaging modalities. Furthermore, the emerging role of artificial intelligence in ophthalmic imaging was reviewed. This article summarizes the presentations, discussion, and future directions.
Assuntos
Oftalmopatias/diagnóstico por imagem , Olho/diagnóstico por imagem , Lasers , Oftalmoscópios , Oftalmoscopia , Avaliação da Tecnologia Biomédica , Tomografia de Coerência Óptica/instrumentação , Inteligência Artificial , Difusão de Inovações , Humanos , Interpretação de Imagem Assistida por Computador , Lasers/efeitos adversos , Oftalmoscópios/efeitos adversos , Oftalmoscopia/efeitos adversos , Segurança do Paciente , Valor Preditivo dos Testes , Medição de Risco , Fatores de Risco , Tomografia de Coerência Óptica/efeitos adversos , Estados Unidos , United States Food and Drug AdministrationRESUMO
There exists a public health imperative to discover and to develop disease-modifying Alzheimer's disease (AD) therapeutics to protect the health of millions of individuals facing AD. Achievement of this goal will be dependent on developing the clinical tools to detect high risk, in the earliest phases of the disease, and at the population level. This article describes the study of retinal biomarkers for the identification of, and tracking of change over time for, individuals in the preclinical stage of AD and substantiates the need for a major cross-disciplinary effort for comparison across labs and clinical sites using diabetes risk monitoring as a perfect analogy. Proposed framework would: (1) support AD working groups across disciplines; (2) establish common imaging platforms to develop and test basic standards, and minimum datasets to embrace and test novel innovations as they emerge; and (3) accelerate AD prevention and quality improvement in real-world care.
Assuntos
Doença de Alzheimer/diagnóstico , Doença de Alzheimer/terapia , Diabetes Mellitus/terapia , Equipe de Assistência ao Paciente , Retina/diagnóstico por imagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores , Progressão da Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neuroimagem , População , Melhoria de Qualidade , Medição de RiscoRESUMO
PURPOSE: To examine the different dimensions of access to eye care from a public health perspective. METHODS: We substantively review the theoretical and empirical literature on access to eye care and summarize the major considerations in measuring access to eye care using a modified behavioral framework. RESULTS: We found that progress has been made, but some gaps still remain in measuring access to eye care. Most studies have focused on individual characteristics and use of eye care services. Only a very few studies have touched on contextual characteristics, such as demographic make-up of the area in which the patient lives, and their impact on the use of eye care services. Few studies have explored the linkage between the use of eye care services and outcomes or between the use of such services and patient satisfaction. CONCLUSIONS: To address a variety of demands from patients, providers, and policy makers, it is necessary to account for potential access and realized access measures. We need to adopt new methods in assessing the relationship between contextual characteristics and use of eye care services. Moreover, we need to better understand patients' satisfaction and their relationship with utilization and health outcomes.
Assuntos
Oftalmopatias/terapia , Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Saúde Pública , Humanos , Seguro Saúde/estatística & dados numéricos , Estados UnidosRESUMO
OBJECTIVE: To estimate the levels of self-reported access of eye care services in the nation. METHODS: We analyzed data from the 2002 National Health Interview Survey (30 920 adults aged > or =18 years). We estimated the number of US adults at high risk for serious vision loss and assessed factors associated with the use of eye care services. RESULTS: An estimated 61 million adults in the United States were at high risk for serious vision loss (they had diabetes, had vision or eye problems, or were aged > or =65 years); 42.0% of the 78 million adults who had dilated eye examinations in the past 12 months were among this group. Among the high-risk population, the probability of having a dilated eye examination increased with age, education, and income (P<.01). The probability of receiving an examination was higher for the insured, women, persons with diabetes, and those with vision or eye problems (P<.01). Approximately 5 million high-risk adults could not afford eyeglasses when needed; being female, having low income, not having insurance, and having vision or eye problems were each associated with such inability (P<.01). CONCLUSIONS: There is substantial inequity in access to eye care in the United States. Better targeting of resources and efforts toward people at high risk may help reduce these disparities.